

2016

Genetic ablation of calcium-independent phospholipase A2 γ induces glomerular injury in mice

Hanan Elimam
McGill University

Joan Papillon
McGill University

Daniel R. Kaufman
McGill University

Julie Guillemette
McGill University

Lamine Aoudjit
McGill University

See next page for additional authors

Follow this and additional works at: http://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation

Elimam, Hanan; Papillon, Joan; Kaufman, Daniel R.; Guillemette, Julie; Aoudjit, Lamine; Gross, Richard W.; Takano, Tomoko; and Cybulsky, Andrey V., "Genetic ablation of calcium-independent phospholipase A2 γ induces glomerular injury in mice." *The Journal of Biological Chemistry*. 291, 28. 14468-14482. (2016).
http://digitalcommons.wustl.edu/open_access_pubs/5512

Authors

Hanan Elimam, Joan Papillon, Daniel R. Kaufman, Julie Guillemette, Lamine Aoudjit, Richard W. Gross, Tomoko Takano, and Andrey V. Cybulsky

Genetic Ablation of Calcium-independent Phospholipase A₂γ Induces Glomerular Injury in Mice*

Received for publication, October 5, 2015, and in revised form, April 19, 2016. Published, JBC Papers in Press, May 12, 2016, DOI 10.1074/jbc.M115.696781

Hanan Elimam^{†1}, Joan Papillon[‡], Daniel R. Kaufman[‡], Julie Guillemette[‡], Lamine Aoudjit[‡], Richard W. Gross[§], Tomoko Takano^{‡2}, and Andrey V. Cybulsky^{‡3}

From the [†]Department of Medicine, McGill University Health Centre Research Institute, McGill University, Montreal, Quebec H4A 3J1, Canada and the [§]Department of Medicine, Washington University School of Medicine, St. Louis, Missouri 63110

Glomerular visceral epithelial cells (podocytes) play a critical role in the maintenance of glomerular permselectivity. Podocyte injury, manifesting as proteinuria, is the cause of many glomerular diseases. We reported previously that calcium-independent phospholipase A₂γ (iPLA₂γ) is cytoprotective against complement-mediated glomerular epithelial cell injury. Studies in iPLA₂γ KO mice have demonstrated an important role for iPLA₂γ in mitochondrial lipid turnover, membrane structure, and metabolism. The aim of the present study was to employ iPLA₂γ KO mice to better understand the role of iPLA₂γ in normal glomerular and podocyte function as well as in glomerular injury. We show that deletion of iPLA₂γ did not cause detectable albuminuria; however, it resulted in mitochondrial structural abnormalities and enhanced autophagy in podocytes as well as loss of podocytes in aging KO mice. Moreover, after induction of anti-glomerular basement membrane nephritis in young mice, iPLA₂γ KO mice exhibited significantly increased levels of albuminuria, podocyte injury, and loss of podocytes compared with wild type. Thus, iPLA₂γ has a protective functional role in the normal glomerulus and in glomerulonephritis. Understanding the role of iPLA₂γ in glomerular pathophysiology provides opportunities for the development of novel therapeutic approaches to glomerular injury and proteinuria.

Phospholipase A₂ (PLA₂)⁴ enzymes catalyze the cleavage of the *sn*-2-ester bond of phospholipids to yield free fatty acids, such as arachidonic acid, and lysophospholipids (1–3). Both

products represent precursors for signaling molecules that can exert multiple biological functions. Calcium-independent PLA₂s (iPLA₂s) are members of the group VI family of PLA₂ enzymes (3, 4). Group VIB (iPLA₂γ) is homologous to iPLA₂β in the C-terminal catalytic domain but shows no similarities in the N-terminal region; accordingly, iPLA₂γ has regulatory properties distinct from those of iPLA₂β (3, 5, 6).

Genetic ablation of iPLA₂γ in mice resulted in the generation of viable progeny that demonstrated reduced growth rate as well as cold intolerance due to impaired fat burning in brown adipose tissue and mitochondrial dysfunction (3, 7). Several studies showed that iPLA₂γ KO mice display multiple bioenergetic dysfunctional phenotypes. For example, iPLA₂γ deletion induced profound alterations in hippocampal phospholipid metabolism and mitochondrial phospholipid homeostasis, resulting in enlarged and degenerating mitochondria, leading to enhanced autophagy and cognitive dysfunction (8). Another recent study showed that genetic ablation of iPLA₂γ prevented obesity and insulin resistance during high fat feeding by mitochondrial uncoupling and increased adipocyte fatty acid oxidation (9). Taken together, these reports confirm an obligatory role for iPLA₂γ in mitochondrial lipid metabolism and membrane structure, perturbation of which may profoundly influence fatty acid β-oxidation, oxygen consumption, energy expenditure, and, thus, tissue homeostasis. Despite the recent advances in studying the pathophysiological role of iPLA₂γ in the brain, liver, heart, and skeletal muscles (7, 8, 10, 11), the pathophysiological roles of iPLA₂γ in the kidney are poorly understood.

Visceral glomerular epithelial cells (GECs), also known as podocytes, are highly differentiated cells of the kidney glomerulus, which play a critical role in the maintenance of glomerular permselectivity (12–14). Podocytes have a complex morphology that is characterized by cell bodies with projecting foot processes, which adhere to the glomerular basement membrane (GBM). The unique shape of podocytes is supported by the actin cytoskeleton, which allows podocytes to alter their shape dynamically (12, 15). In many renal diseases, changes in the size and surface charge of podocytes contribute to the development of proteinuria. Specifically, proteinuria is associated with the disruption of the foot processes with the concomitant transformation of the actin cytoskeleton (12–15). Thus, the intricate structure of foot processes is central to their function of maintaining glomerular permselectivity (*i.e.* filtration of plasma but restriction of proteins). Various forms of glomerulonephritis, including those induced by antibody and comple-

* This work was supported by Canadian Institutes of Health Research Grants MOP-53264, MOP-133492, MOP-125988, and MOP-53335; National Institutes of Health Grant RO1 HL118639; and the Catherine McLaughlin Hakim Chair (to A. V. C.). The authors declare that they have no conflicts of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

¹ Present address: Dept. of Biochemistry, Misr International University, km 28 Cairo-Ismaïlia Rd., Cairo, Egypt.

² To whom correspondence may be addressed: Division of Nephrology, Research Institute EM13244, 1001 Decarie Blvd., Montreal, Quebec H4A 3J1, Canada. Tel.: 514-934-1934 (ext. 76180); Fax: 514-933-8784; E-mail: tomoko.takano@mcgill.ca.

³ To whom correspondence may be addressed: Division of Nephrology, Research Institute EM13238, 1001 Decarie Blvd., Montreal, Quebec H4A 3J1, Canada. Tel.: 514-934-1934 (ext. 76299); Fax: 514-933-8784; E-mail: andrey.cybulsky@mcgill.ca.

⁴ The abbreviations used are: PLA₂, phospholipase A₂; iPLA₂, calcium-independent phospholipase A₂; AMPK, AMP-activated protein kinase; ER, endoplasmic reticulum; GBM, glomerular basement membrane; GEC, glomerular epithelial cell; LC3, microtubule-associated protein light chain 3; LDH, lactate dehydrogenase; WT1, Wilms tumor-1.

ment, are associated with podocyte injury, which may lead to foot process effacement, detachment from the GBM, or apoptosis, with consequent impairment of glomerular function and permselectivity (proteinuria), and glomerulosclerosis (13, 16–18).

Previously, we characterized the expression and activity of iPLA₂γ in cultured GECs and characterized the mechanisms of iPLA₂γ activation by complement C5b-9 (19, 20). In GECs, we demonstrated that iPLA₂γ is localized at the endoplasmic reticulum (ER) and mitochondria, and this localization was dependent on the N-terminal region of iPLA₂γ (20). Complement stimulated the activation of iPLA₂γ, which was mediated via the extracellular signal-regulated kinase and p38 pathways. Stimulation of iPLA₂γ was dependent on phosphorylation of Ser-511 and/or Ser-515 via MNK1 (MAPK-interacting kinase 1) (20). In addition to characterizing these signaling pathways, we showed that overexpression of iPLA₂γ in cultured GECs reduced complement-mediated GEC injury (19) as well as injury by tunicamycin, which was associated with augmentation of the ATF6 (activating transcription factor 6) pathway of the unfolded protein response in the ER (21). In other cells, such as primary cultures of rabbit renal proximal tubules cells, knockdown of iPLA₂γ expression increased lipid peroxidation and impaired mitochondrial function (22). Likewise, knockdown of iPLA₂γ in C2C12 myoblasts also caused an elevation of lipid peroxidation and reduction of ATP synthesis (11). Thus, the function of iPLA₂γ can be cytoprotective, and depending on the cellular context, it may involve ER stress or removal of peroxidized phospholipid from the mitochondrial membrane, thereby preserving membrane integrity.

So far, we and others have provided considerable insight into the functions of iPLA₂γ in cultured cell lines, but information on the functional role of iPLA₂γ in the kidney is lacking. The aim of the present study was to employ iPLA₂γ KO mice to better understand the role of iPLA₂γ in normal glomerular/podocyte function and in glomerular injury. We show that deletion of iPLA₂γ did not cause albuminuria; however, it resulted in mitochondrial structural abnormalities and enhanced autophagy in podocytes of aging mice. Moreover, after induction of anti-GBM nephritis in young mice, iPLA₂γ KO mice exhibited significantly increased levels of albuminuria, podocyte injury, and loss of podocytes compared with WT mice. Our results indicate that iPLA₂γ has a protective functional role in the normal glomerulus and in glomerulonephritis.

Experimental Procedures

Materials—A mouse albumin ELISA quantification kit was purchased from Bethyl Laboratories (Montgomery, TX). The creatinine assay kit was from Cayman Chemical Co. (Ann Arbor, MI). Tissue culture media and Lipofectamine 2000 were from Invitrogen (Burlington, Canada) and Wisent (Saint-Jean-Baptiste, Canada). Electrophoresis reagents were from Bio-Rad (Mississauga, Canada), and GE Healthcare (Baie d'Urfé, Canada). Rabbit anti-Wilms tumor-1 (WT1; catalog no. 192), goat anti-synaptopodin (catalog no. 21537), rabbit anti-GRP94 (catalog no. 11402), and rat anti-GRP78 (BiP; catalog no. 13539) antibodies were purchased from Santa Cruz Biotechnology. Goat anti-podocalyxin antibody (catalog no. AF1556) was from

R&D Systems (Minneapolis, MN). Rabbit anti-microtubule-associated protein light chain 3B (LC3; catalog no. 2775), rabbit anti-phospho-AMP-activated protein kinase (AMPK)-α (Thr-172; catalog no. 2531), and rabbit anti-AMPKα (catalog no. 2532) antibodies were from Cell Signaling Technology (Danvers, MA). FITC-conjugated rabbit anti-sheep IgG (catalog no. 31509) was from Zymed Laboratories Inc. (South San Francisco, CA). FITC-conjugated goat anti-mouse complement C3 (catalog no. 55500) was purchased from MP Biomedical (Santa Ana, CA). MitoTracker Red CMXRos was from Thermo Fisher Scientific (Burlington, ON). Plasmid pBABE-puro mCherry-EGFP-LC3B was from Addgene (catalog no. 22418) (23). Plasmid “mito-YFP” (cytochrome *c* oxidase-subunit IV fused with yellow fluorescent protein; catalog no. 10089272) was from the American Type Culture Collection (Manassas, VA). Sheep anti-rat GBM, and rabbit anti-nephrin antisera were described previously (24, 25).

Mice—iPLA₂γ KO mice in a C57BL/6 background were produced, bred, and genotyped, as described previously (7). Animal protocols were reviewed and approved by the McGill University Animal Care Committee. Conscious animals fed *ad libitum* were weighed, and urine samples were collected at various time points after weaning up to 12–16 months of age.

Assays for Albuminuria and Serum Creatinine—Mouse urine albumin concentration was quantified using an enzyme-linked immunosorbent assay kit according to the manufacturer's instructions. The assay utilizes urine samples diluted 1:5000 or 1:150,000, analyzed in a plate reader set at 450 nm. Urine creatinine concentration was measured using a colorimetric assay kit according to the manufacturer's instructions. The assay measures creatinine in urine samples diluted 1:15, using a picric acid-based method, and analyzed on a plate reader set at 490–500 nm. Excretion of albumin is expressed as the albumin/creatinine ratio. Serum creatinine was measured using an enzymatic assay on the Olympus AU5822 chemistry system (Beckman Coulter) in the Biochemistry Laboratory of the McGill University Health Centre.

Induction of Anti-GBM Nephritis in Mice—Anti-GBM nephritis was induced in 3–4-month-old iPLA₂γ KO or WT mice by a single tail intravenous injection of 5–10 μl of sheep anti-GBM antiserum diluted in 0.1 ml of sterile saline (24, 26). After 24 h, mice were sacrificed by CO₂ asphyxiation, and kidneys were dissected. Kidney sections were collected for immunofluorescence, light, and electron microscopy (see below). Glomeruli were isolated utilizing a differential sieving technique (24).

Cell Culture and Complement Cytotoxicity Assay—Mouse GECs were derived from iPLA₂γ KO mice and WT control. The detailed method and characterization of the cells was published previously (21). Briefly, by quantitative reverse polymerase chain reaction, iPLA₂γ mRNA was present in cells derived from WT mice but was completely absent in cells from KO mice. WT and KO cell lines expressed the podocyte proteins, synaptopodin and nephrin (12, 14, 21). The cells were cultured on plastic substratum in K1 medium and were used at passages 2–20. Cells were transfected with pBABE-puro mCherry-EGFP-LC3B, using Lipofectamine 2000 reagent according to the manufacturer's instructions.

Rat GECs were cultured as described above and were characterized previously (19–21, 26). These cells were employed in the complement cytotoxicity assay (19, 20, 26). Briefly, rat GECs were incubated with rabbit anti-GEC antiserum (5%, v/v) in modified Krebs-Henseleit buffer containing 145 mM NaCl, 5 mM KCl, 0.5 mM MgSO₄, 1 mM Na₂HPO₄, 0.5 mM CaCl₂, 5 mM glucose, and 20 mM Hepes, pH 7.4, for 30 min at 22 °C. The cells were then incubated for 40 min at 37 °C with normal human serum (with full complement activity) or heat-inactivated (decomplemented) human serum (incubated at 56 °C for 60 min) in controls. Complement-mediated cytolysis was determined by measuring lactate dehydrogenase (LDH) release (19, 26). Specific LDH release was calculated as $(NS - HIS)/(100 - HIS)$, where *NS* represents the percentage of total LDH released into cell supernatants in incubations with normal serum, and *HIS* represents the percentage of total LDH released in incubations with heat-inactivated serum.

Immunofluorescence Microscopy—Kidney poles were snap-frozen using HistoPrep (Fisher Scientific, Ottawa, Canada) in isopentane (−80 °C). Cryostat sections (4 μ m) were cut and stored at −80 °C. Frozen sections were then fixed in 4% paraformaldehyde and blocked with 5% normal rabbit serum (for sheep IgG) or goat serum (for C3) in 5% BSA or in 5% BSA alone (for synaptopodin, podocalyxin, and nephrin antibodies). The blocking solution was replaced with a fluorophore-conjugated primary antibody or, alternatively, with an unconjugated primary antibody, followed by a fluorophore-conjugated secondary antibody. Incubations with primary antibodies ranged from 2 h to overnight (4 or 22 °C). Incubations with secondary antibodies were 1 h at 22 °C. Sections were examined with a Zeiss AxioObserver fluorescence microscope with visual output connected to an AxioCam digital camera. Images of multiple glomeruli were collected from series of images derived from different focal planes (*z*-stack). To allow comparisons of fluorescence intensity, all images were taken at the same exposure. Fluorescence intensity was quantified using the histogram function of Adobe Photoshop or ImageJ software (National Institutes of Health, Bethesda, MD). Results are expressed in arbitrary units.

For WT1 immunofluorescence, frozen sections were fixed with 4% paraformaldehyde and then immersed in 10 mmol/liter sodium citrate, pH 6.0, for 8 min at 100 °C. After cooling to 22 °C, sections were blocked with 10% normal goat serum and were incubated with rabbit anti-WT1 antibody (4 °C, overnight), followed by rhodamine-goat anti-rabbit IgG (22 °C, 1 h). WT1-positive cells were quantified by visual counting.

To visualize mitochondria, cells on coverslips were incubated for 15–30 min at 37 °C with MitoTracker Red CMXRos (25 nM). Hoechst H33342 (1 μ g/ml) was added for the final 5 min to label nuclei. Cells were then fixed with paraformaldehyde. After washing, coverslips were mounted onto glass slides and visualized with a fluorescence microscope (20).

GFP and mCherry-LC3-II puncta in cells can be readily distinguished from background fluorescence and quantified using ImageJ software. Green and red images were separately converted to grayscale. Cell contours on grayscale images were selected with the freehand tool, and the area of the cross-section was measured. Then image histogram plots were obtained, representing the range of pixel brightness values in each image.

The threshold intensity was set at the end of the histogram declining slope (thereby only including the brightest fluorescent puncta and omitting cellular features and background). The area of LC3-II puncta was set between 0.2 and 25 μ m². The number of particles/puncta and total cross-sectional area of the particles/puncta whose areas fell within the set range of 0.2–25 μ m² were measured. Results were normalized per 1000 μ m² of cell area. The image calculator function (subtract operation) was used to calculate the mCherry-LC3-II particles/puncta that did not colocalize with GFP-LC3-II.

Light and Electron Microscopy—For light microscopy, kidney tissue was fixed in formalin, and was processed and embedded in paraffin according to conventional techniques. Sections were stained with periodic acid Schiff at the Goodman Cancer Research Center Histology Facility, McGill University. Electron microscopy was carried out at the McGill University Facility for Electron Microscopy Research. Briefly, kidney tissue was fixed in 2.5% glutaraldehyde in 0.1 mol/liter sodium cacodylate buffer containing 0.1% CaCl₂, pH 7.4. Samples were washed and postfixed with 1% aqueous OsO₄ and 1.5% aqueous potassium ferrocyanide. Then samples were dehydrated with serially increasing concentrations of acetone (from 30 to 100%) and were infiltrated with epon/acetone. Sections of 90–100 nm were placed onto grids and stained with uranyl acetate and Reynold's lead. Samples were viewed with an FEI Tecnai 12 transmission electron microscope operating at an accelerating voltage of 120 kV and equipped with an AMT XR80C CCD camera.

Quantification of Foot Process Effacement and Glomerular Surface Area—Randomly selected electron micrographs were used for morphometric analysis of foot process effacement, as described previously (27, 28), using ImageJ software. The mean width of the foot process (*FPW*) was calculated according to the formula (27), $FPW = (\pi \times \text{glomerular basement membrane length}) / (4 \times \text{foot process number})$.

A greater foot process width value represents increased foot process effacement. Three capillary loops from 2–3 glomeruli/mouse were quantified, and the results from 3–5 mice/group were pooled and analyzed. Glomerular cross-sectional surface area was measured in light micrographs of KO and WT mice, using ImageJ software.

Immunoblot Analysis—Lysates of isolated glomeruli (24) were prepared in buffer containing 1% Triton X-100, 125 mM NaCl, 10 mM Tris (pH 7.4), 1 mM EGTA, 2 mM Na₃VO₄, 10 mM sodium pyrophosphate, 25 mM NaF, and protease inhibitor mixture (Bioshop, Burlington, Canada). Equal amounts of lysate proteins were dissolved in Laemmli buffer and were subjected to SDS-PAGE under reducing conditions. Proteins were then electrophoretically transferred onto nitrocellulose or polyvinylidene difluoride membranes and blocked at 22 °C for 1 h with 5% BSA in buffer containing 10 mM Tris, pH 7.5, 50 mM NaCl, 2.5 mM EDTA, and 0.05% Tween 20. The membrane was then incubated with primary and secondary antibodies. Bands were detected by an enhanced chemiluminescence system (GE Healthcare, Mississauga, Canada). Quantitative densitometry was performed using ImageJ (25).

Statistics—Data are presented as mean \pm S.E. One-way analysis of variance was used to determine significant differences




FIGURE 1. *iPLA₂γ* deletion does not alter urinary albumin excretion in mice. A, urinary albumin/creatinine ratio. Each point represents the urine collection of a single mouse taken at monthly intervals between 4 and 16 months (*mo*) of age. WT and *iPLA₂γ* KO mice were divided into groups according to sex (male (M) and female (F)). There are no significant differences among the groups. B, glomerular surface area was measured in light micrographs of KO and WT mice (age 10–11 months). There were no significant differences between groups (3 mice/group; 14–24 measurements/group). Error bars, S.E.

among groups. Where significant differences were found, individual comparisons were made between groups using Student's *t* test and adjusting the critical value according to Bonferroni's method. Student's *t* test was used to determine significant differences between two groups.

Results

***iPLA₂γ* Deletion Does Not Affect Baseline Urinary Albumin Excretion**—General phenotypic features of mice null for *iPLA₂γ* were described previously (7, 11). In keeping with the earlier report, modest growth retardation was visible in KO mice after 2 months of age. At 3–4 months, *iPLA₂γ* KO animals (males and females) had a mean weight of 22.09 ± 0.75 g *versus* 26.02 ± 0.84 g for WT ($p < 0.005$, $n = 9$ –10 mice/group). There was no significant difference in weight between males and females within the same groups. To determine whether deletion of *iPLA₂γ* can affect glomerular permeability and induce proteinuria, we quantified the urine albumin/creatinine ratio. Mice at 4–7 months of age showed a low albumin/creatinine ratio, and there was no significant difference between KO and WT mice (Fig. 1A). Urine albumin tended to be slightly higher in male mice compared with females. The albumin/creatinine ratio between WT and age/sex-matched KO mice did not differ significantly up to 16 months of age (Fig. 1). Serum creatinine values were 9.3 ± 0.7 μM in 10–12-month-old *iPLA₂γ* KO mice and 12.1 ± 0.9 μM in WT ($p = 0.02$; 7–8 mice/group). The lower mean value in the KO mice is consistent with lower body weight. Light microscopy (periodic acid Schiff staining) showed normal glomerular and tubular morphology in both WT and KO mice 10–12 months of age (results not shown). To confirm the visual impression, glomerular surface area was measured in light micrographs of KO and WT mice. There were no significant differences between groups (Fig. 1B).

***iPLA₂γ* Deletion Induces Mitochondrial Damage and Autophagy in Podocytes**—Given that *iPLA₂γ* is localized in GECs at the ER and mitochondria (20), we hypothesized that deletion of *iPLA₂γ* may induce abnormalities in these organelles. Kidneys of *iPLA₂γ* KO and WT control mice at age 10–11 months were examined by electron microscopy. Podocyte foot


processes appeared structurally intact in both *iPLA₂γ* KO mice (Fig. 2A) and WT controls (not shown). WT mice showed no apparent glomerular abnormalities, and in particular, podocytes showed intact cell organelles, including the ER and mitochondria (Fig. 2B). In contrast, some podocytes in *iPLA₂γ* KO mice showed microvillous transformation and membrane vesiculation, compatible with podocyte injury (Fig. 2C). The striking observation in *iPLA₂γ* KO mice was that podocytes showed abnormal mitochondria and the presence of autophagic vacuoles (Fig. 2, D–I). The mitochondrial abnormalities were widespread and included aggregation, disruption of membranes, and loss/rearrangement of cristae (Fig. 2, F and H), whereas some mitochondria appeared to be undergoing fission (Fig. 2F).

We analyzed all high power electron micrographs to quantify damaged mitochondria and autophagosome structures in podocytes. In 5 *iPLA₂γ* KO mice, damaged mitochondria were observed in 54% of the micrographs, and damaged autophagosomes were seen in 17%. Forty percent of the micrographs showed both normal mitochondria and an absence of autophagosomes (35 high power electron micrographs were examined in total). In three WT mice, there were no damaged mitochondria nor any autophagosomes (17 electron micrographs were examined).

It should also be noted that, unlike podocytes, mitochondria in parietal epithelial cells, glomerular endothelial cells, and proximal tubular epithelial cells in *iPLA₂γ* KO mice appeared normal (Fig. 2, D, H, and J). In contrast to the mitochondria in *iPLA₂γ* KO podocytes, the ER and nuclei appeared intact (Fig. 2, E–I). Quantification of foot process width in *iPLA₂γ* KO and WT mice demonstrated modest but significant widening of foot processes in the KO (Fig. 2K). Thus, deletion of *iPLA₂γ* in mice induces prominent mitochondrial abnormalities, autophagy, and modest widening of the foot processes and plasma membrane changes in podocytes.

***iPLA₂γ* Deletion Induces Podocyte Loss but Not ER Dysfunction in Podocytes**—The above results showed that *iPLA₂γ* deletion affected podocyte ultrastructure; consequently, podocyte-associated proteins that are believed to play key roles in maintaining ultrastructure and slit diaphragms (nephrin, synaptopodin, and podocalyxin) (12, 14, 26, 29) were examined by immunofluorescence microscopy and immunoblot analysis. The podocyte nuclear marker, WT1, was also studied as an index of podocyte number (12, 14, 26, 29). Kidney sections from *iPLA₂γ* KO and WT mice (age 10–11 months) were stained with specific antibodies. Synaptopodin, nephrin, and podocalyxin showed an immunofluorescence staining pattern consistent with expression in podocytes in glomeruli of *iPLA₂γ* KO and WT mice, although the intensity of synaptopodin was reduced in the KO (Fig. 3A). Quantification of glomerular fluorescence intensity showed that synaptopodin staining was significantly lower in *iPLA₂γ* KO glomeruli compared with WT (Fig. 3B). Fluorescence intensities of nephrin and podocalyxin staining did not differ significantly between WT and *iPLA₂γ* KO mouse glomeruli, although both tended to decrease in the KO (Fig. 3, C and D).

To determine whether deletion of *iPLA₂γ* induces podocyte loss, we quantified the number of podocyte nuclei in glomeruli






FIGURE 3. **Expression of synaptopodin, nephrin, podocalyxin, and WT1 in 10–11-month-old WT and *iPLA₂γ*-KO mice.** A, kidney sections were stained with specific antibodies and were examined by immunofluorescence microscopy. Bar, 20 μ m. B–D, quantification of fluorescence intensity in arbitrary units (3–7 glomeruli/mouse in three KO and two WT mice, or 11–18 glomeruli/group, were analyzed). B, synaptopodin: $p < 0.0002$, KO versus WT. E, WT1-positive (pos) nuclei: $p < 0.0001$, KO versus WT (6–12 glomeruli/mouse in three KO and two WT mice, or 34–55 glomeruli/group, were analyzed). Error bars, S.E.

of *iPLA₂γ* KO and WT mice using WT1 immunostaining. There was a ~25% decrease in the number of WT1-positive cells in *iPLA₂γ* KO glomeruli compared with control (Fig. 3, A and E), indicating that deletion of *iPLA₂γ* induced a loss of podocytes. This result does not, however, exclude the possibility that a reduction in WT1-positive cells might have been related to injury instead of loss of cells.

Immunoblotting of glomerular lysates showed that expression of nephrin and podocalyxin proteins was not significantly different between *iPLA₂γ* KO and WT mice. Synaptopodin was reduced in the KO (Fig. 4, A–D), consistent with the immunofluorescence staining (Fig. 3, B–D). Nephrin undergoes important post-translational modifications in the ER before export to the plasma membrane (25). By SDS-PAGE, nephrin migrates as a doublet of ~180 kDa. The upper band represents the fully glycosylated, mature form of nephrin, whereas the lower band is an immature form found in the ER (25, 26). To address the role of *iPLA₂γ* in ER function *in vivo*, we examined the pattern of nephrin glycosylation in isolated glomeruli by immunoblotting. There were no apparent differences in nephrin glycosylation between *iPLA₂γ* KO and WT mice (Fig. 4B, bottom), sug-

gesting that ER function remained intact despite *iPLA₂γ* deletion.

In a previous study (21), we demonstrated that in cultured GECs, *iPLA₂γ*, via its localization at the ER, amplified the activation of the ATF6 pathway of the unfolded protein response. Amplification of ATF6 resulted in the up-regulation of the ER chaperones, GRP78 (BiP) and GRP94 (21). Conversely, deletion of *iPLA₂γ* blunted these responses, as shown in cultured GECs derived from WT and *iPLA₂γ* KO mice (21). Therefore, we undertook to examine the expression of ER chaperones in podocytes *in vivo* by immunoblotting. Unexpectedly, there was no significant difference in the glomerular GRP94 expression between WT and *iPLA₂γ* KO mice (Fig. 4, A and E). A similar result was obtained with GRP78 (BiP) expression (result not shown). Therefore, either differences in ER chaperone expression between WT and *iPLA₂γ* KO mice were too small to be detected *in vivo*, or additional factors regulate the expression of these proteins *in vivo* compared with in cultured cells.

***iPLA₂γ* Deletion Reduces Mitochondrial Function**—The electron micrographs of *iPLA₂γ* KO mice showed striking mitochondrial abnormalities (Fig. 2). To determine whether these

FIGURE 2. **Kidney cell ultrastructure in 10–11-month-old mice (electron microscopy).** A, podocyte foot processes in *iPLA₂γ*-KO mice appeared structurally intact. B, podocyte from a WT, control mouse shows intact cell organelles, including mitochondria. C, podocytes from an *iPLA₂γ* KO mouse show microvillous transformation and membrane vesiculation (arrows). D–I, podocytes from *iPLA₂γ*-KO mice show abnormal mitochondria and autophagic vacuoles. F and H, magnified views of the areas in E and G outlined by boxes, respectively. Mitochondria in podocytes show aggregation, disruption of membranes, and loss of cristae (arrowheads in F and H), whereas some mitochondria appear to be undergoing fission (F). In D and I, the closed arrows point to autophagosomes in podocytes. Mitochondria in a parietal epithelial cell (open arrow, D) and a glomerular endothelial cell (open arrow, H) appear normal. The ER (F and H) and nuclei (E–I) in podocytes appear intact. J, proximal tubular epithelial cell from an *iPLA₂γ*-KO mouse shows normal mitochondria. The brush border is seen on the top right of the photomicrograph. Bar, 500 nm. Glomeruli were examined in five KO and three WT mice, 2–3 glomeruli/mouse. K, quantification of foot process width in *iPLA₂γ*-KO and WT mice. *, $p < 0.0005$ KO versus WT (21–22 measurements/group). Error bars, S.E.




FIGURE 4. Effect of *iPLA₂γ* deletion on expression of nephrin (fully glycosylated and ER forms), podocalyxin, GRP94, synaptopodin (synpo), phospho-AMPK (pAMPK), AMPK, and LC3-I and -II. Glomeruli were isolated from 10–11-month-old WT and *iPLA₂γ*-KO mice. Lysates were immunoblotted, as indicated. A, representative immunoblots. The white lines in the top panel indicate reassembly of noncontiguous gel lanes. There were no adjustments made to the digital images among the lanes that would alter the information in the panels. B–G, densitometric quantification. B, C, and E, there were no significant differences in the expression of fully glycosylated nephrin (top nephrin band), nephrin maturation (ratio of top to bottom band), podocalyxin, and GRP94 between groups (3–5 mice/group). D, synaptopodin was significantly lower in KO glomeruli. *, $p < 0.05$, 3 mice/group. F, the ratio of phospho-AMPK/AMPK was significantly greater in KO glomeruli. *, $p < 0.04$, 4 mice/group. G, the ratio of LC3-II/LC3-I was significantly greater in KO mice. *, $p = 0.01$, 7–9 mice/group. Because the intensity of the LC3-I band in A was relatively weak, the immunoblot was repeated using a longer exposure time. This resulted in enhanced signals in LC3-I bands, although the signals of the LC3-II bands became oversaturated. Nevertheless, the LC3-II/LC3-I ratio remained significantly elevated in the KO mice compared with WT (results not shown). Error bars, S.E.

mitochondrial abnormalities were associated with impaired mitochondrial function *in vivo*, we monitored phosphorylation of AMPK, a ubiquitous serine/threonine kinase (30, 31). During periods of cellular stress, particularly when there is a decrease in ATP, and increases in ADP and AMP, binding of ADP or AMP activates AMPK by facilitating phosphorylation and inhibiting dephosphorylation of Thr-172 in the α -subunit. Thus, AMPK acts as a sensor of cell energy stores, and phosphorylation of AMPK is inversely related to the cell's ATP level. The mean glomerular phospho-AMPK level was clearly increased in *iPLA₂γ* KO mice compared with control, although there was some variability among animals (Fig. 4, A and F). This result is in keeping with reduced ATP generation by mitochondria in podocytes.

To provide additional support for the conclusion that deletion of *iPLA₂γ* impaired mitochondrial function, we examined Mitotracker Red CMXRos staining in cultured GECs produced

from WT and *iPLA₂γ* KO mice (21). Mitotracker Red CMXRos is a fluorescent dye that stains mitochondria in live cells, and its accumulation is dependent on the mitochondrial membrane potential. In WT cells, the mitochondria stained brightly and localized diffusely throughout the cytoplasm (Fig. 5, A and C). In these cells, the mitochondria appeared as short tubular structures, and they did not form long filaments. In most of the *iPLA₂γ* KO cells, cytoplasmic staining was faint or absent, and the mitochondria appeared aggregated in a perinuclear distribution (Fig. 5, A and C). The latter resembled the staining of Mitotracker Red CMXRos in WT GECs that had been treated with antimycin A (Fig. 5A). This drug disrupts mitochondrial function by blocking the electron transport chain and results in loss of fluorescent probe from mitochondria (32). It should be noted that, in contrast to the Mitotracker Red CMXRos staining, there were no differences in the expression of transfected mito-YFP (YFP targeted to mitochondria)




FIGURE 5. Mitochondrial function in cultured GECs. A, WT or *iPLA₂γ* KO GECs were incubated with Mitotracker Red CMX-Ros (25 nM for 30 min). In most WT cells, the mitochondria stained brightly and were found diffusely throughout the cytoplasm. In many *iPLA₂γ* KO cells, cytoplasmic staining was faint or absent, and the mitochondria were collapsed in a perinuclear distribution. The latter resembled the staining of Mitotracker Red in WT podocytes that had been treated with antimycin A (WT+A; 10 μ M for 30 min) to induce mitochondrial dysfunction. Bar, 15 μ m. Cells showing diffuse, perinuclear, and intermediate Mitotracker Red CMX-Ros staining patterns are quantified in the graph (C; intermediate pattern indicates perinuclear localization but with some diffuse staining). *, $p < 0.0005$; **, $p < 0.0001$, KO versus WT (170 KO cells and 228 WT cells). B, GECs were transiently transfected with mito-YFP. Images were obtained after 24 h. In transfected cells, expression of mito-YFP was comparable between KO and WT cells. The inset (C) shows quantification of YFP fluorescence intensity in arbitrary units (a.u.) (22–30 cells/group). Error bars, S.E.

between *iPLA₂γ* KO and WT GECs (Fig. 5, B and C). This reflects similar mitochondrial mass in the two cell lines. Thus, the reduced Mitotracker Red CMXRos staining in *iPLA₂γ* KO GECs indicates impaired mitochondrial function.

***iPLA₂γ* Deletion Induces Autophagy in GECs**—Ultrastructural examination of *iPLA₂γ* KO mice showed autophagic vacuoles in some podocytes (Fig. 2, C–E). The extent of lipidation of LC3 (*i.e.* conversion of LC3-I to LC3-II) is widely used to monitor autophagy, and typically, an increase in the ratio of LC3-II to LC3-I correlates with the number of active autophagosomes (33). We employed immunoblotting to monitor the levels of LC3-I and LC3-II in glomeruli of WT and *iPLA₂γ* KO mice (Fig. 4A). Densitometric quantification showed that the LC3-II/LC3-I ratio was markedly greater in *iPLA₂γ* KO glomeruli compared with WT control (Fig. 4G). These results are in

keeping with the presence of autophagosomes in podocytes in the electron micrographs of *iPLA₂γ* KO mice.

There are some limitations to quantifying enhanced autophagic flux *in vivo*. Thus, to confirm enhanced autophagy and the changes in LC3 in glomeruli, we measured the conversion of LC3-I to LC3-II in cultured GECs from WT and *iPLA₂γ* KO mice (21). GECs were incubated with or without chloroquine for 2 or 6 h. Chloroquine blocks the fusion of autophagosomes with lysosomes, which forms autolysosomes, and therefore prevents autolysosomal protein degradation, allowing us to compare the rate of autophagosome formation in WT and *iPLA₂γ* KO GECs (33). GEC lysates were immunoblotted with anti-LC3 antibody. Deletion of *iPLA₂γ* in cultured GECs resulted in a significantly greater increase in the ratio of LC3-II/LC3-I in KO cells, compared with WT, in the presence of chloroquine at 6 h (Fig. 6A). This result is consistent with enhanced autophagy and is in keeping with the findings *in vivo* (Fig. 4G).

Conversion of LC3-I to LC3-II in cultured GECs was also addressed by monitoring the formation of LC3-II puncta by fluorescence microscopy (23, 33). In these experiments, GECs were transfected with mCherry-GFP-LC3B, encoding LC3 tagged with two fluorescent proteins, mCherry and GFP. mCherry- or GFP-LC3-I is cytoplasmic. GFP is quenched in an acidic environment (*i.e.* in lysosomes), but mCherry is acid-stable; thus, formation of GFP-LC3-II puncta reflects formation of autophagosomes, whereas mCherry-LC3-II puncta reflect formation of autophagosomes and their fusion with lysosomes (23, 33). In resting WT GECs, the distribution of mCherry- and GFP-LC3-I was in a cytoplasmic pattern (Fig. 6B). Quantification confirmed the visual impression that resting cells contained relatively few puncta and that the puncta constituted only a minimal proportion of cell area (Fig. 6C, second columns). Increased formation of GFP-LC3-II puncta and, to a lesser extent, mCherry-LC3-II puncta that did not colocalize with GFP was evident in *iPLA₂γ* KO GECs even in the absence of chloroquine (Fig. 6, B and C, first columns). The addition of chloroquine markedly enhanced GFP-LC3-II puncta in KO cells (Fig. 6, B and C, third column), consistent with the formation of autophagosomes in the KO cells. Chloroquine slightly increased GFP-LC3-II puncta in WT cells, but the change was not significant (Fig. 6, B and C, fourth column). In the presence of chloroquine, prominent mCherry-LC3-II puncta were also increased in KO cells, and most mCherry puncta colocalized with GFP (Fig. 6B). These results reflect LC3-II at autophagosomes and to a minor extent in lysosomes and thus confirm enhanced autophagy in *iPLA₂γ* KO GECs.

***iPLA₂γ* Deletion Exacerbates Albuminuria in Anti-GBM Nephritis**—Our previous studies in cultured GECs demonstrated a protective role for *iPLA₂γ* in injury induced by complement (19) and tunicamycin (21). In addition, the above experiments showed that *in vivo*, *iPLA₂γ* is essential to the maintenance of podocyte integrity under basal conditions. Specifically, deletion of *iPLA₂γ* induced mitochondrial abnormalities with autophagy in older mice. In the next set of experiments, we examined whether induction of podocyte injury with anti-GBM antibody would reveal a protective phenotype of *iPLA₂γ* in young mice. C5b-9-induced GEC/podocyte injury




FIGURE 6. Autophagy is enhanced in $iPLA_2\gamma$ KO GECs in culture. A, deletion of $iPLA_2\gamma$ in GECs increases the ratio of LC3-II/LC3-I. WT or $iPLA_2\gamma$ KO GECs were incubated with or without chloroquine (CQ; 15 μM) for 2 or 6 h. Shown is a representative immunoblot of GEC lysates. Values below the LC3 immunoblot indicate mean \pm S.E. ratios of LC3-II/LC3-I in the eight groups (four experiments). *, $p < 0.03$ KO versus WT at 6 h (+CQ). B, $iPLA_2\gamma$ KO GECs in culture show greater numbers of mCherry- and GFP-LC3-II puncta compared with WT cells (representative fluorescence micrographs). GECs were transiently transfected with mCherry-GFP-LC3B (0.1 μg of plasmid DNA/well). After 24 h, cells were untreated (Untr; -) or treated with 15 μM chloroquine (CQ; +). Images were obtained after 6 h. Bar, 25 μm . The inset (KO-CQ, merged) is an enlargement of the area within the square. C, quantification of GFP-LC3-II puncta and GFP-LC3-II puncta area. Results were normalized per 1000 μm^2 of cell area. In the bars showing the GFP + mCherry LC3-II puncta/area, the GFP and mCherry components are above and below the white line, respectively. The mCherry component is that which did not colocalize with GFP. *, $p < 0.005$, KO-untreated versus WT-untreated; **, $p < 0.0001$, KO-CQ versus WT-CQ; $p < 0.0001$, KO-CQ versus KO-Untr; and ***, $p < 0.01$ WT-CQ versus WT-untreated. +, $p < 0.002$ KO-untreated versus WT-untreated; ++, $p < 0.0001$ KO-CQ versus WT-CQ and $p < 0.0001$ KO-CQ versus KO-untreated (11–12 cells/group). Error bars, S.E.

and proteinuria are hallmarks of heterologous mouse anti-GBM nephritis. Anti-GBM antibody binds in part to podocyte antigens *in vivo*, and heterologous phase proteinuria is abolished by C6 deficiency, indicating a key role of C5b-9 (24, 34, 35). In previous studies, we determined that administration of 5–10 μl of sheep anti-GBM antiserum induces mild to moder-

ate albuminuria (26). Therefore, $iPLA_2\gamma$ KO and WT mice (age 3–4 months) were injected with anti-GBM antiserum, and additional mice in each group were injected with saline (control). Urine samples were collected just before administration of antibody and after 24 h. Both WT and $iPLA_2\gamma$ KO mice developed albuminuria 24 h after induction of anti-GBM nephritis. However, $iPLA_2\gamma$ KO mice exhibited significantly higher levels of albuminuria compared with WT (Fig. 7A).

Deposition of anti-GBM antibody and activation of complement were assessed by immunofluorescence microscopy. There was prominent linear deposition of sheep anti-GBM IgG along the glomerular capillary walls in both WT and $iPLA_2\gamma$ KO mice (Fig. 7B). Glomerular C3 staining was slightly fainter, compared with IgG, but was clearly present in both groups of mice (Fig. 7B). Quantification of IgG and C3 fluorescence intensity did not demonstrate significant differences between the two groups (Fig. 7C). Therefore, the increased albuminuria in $iPLA_2\gamma$ KO mice occurred despite equal glomerular anti-GBM antibody and C3 deposition in WT and $iPLA_2\gamma$ KO mice.

$iPLA_2\gamma$ Deletion Enhances Podocyte Ultrastructural Abnormalities in Anti-GBM Nephritis—After injection of anti-GBM antibody, glomerular and tubular morphology of WT and $iPLA_2\gamma$ KO mice ($n = 6$ –7 mice) appeared normal by light microscopy; in particular, there was no inflammatory cell infiltration in the glomeruli (results not shown). Kidneys of albuminuric (anti-GBM antibody-treated) and control mice (saline-treated groups) were also examined by electron microscopy. The 3-month-old saline-treated KO mice showed no apparent glomerular abnormalities, and podocyte ultrastructure appeared normal (Fig. 8A). Similarly, the saline-treated WT mice showed no ultrastructural abnormalities (result not shown). Anti-GBM-injected WT mice showed focal abnormalities in podocyte ultrastructure (Fig. 8B). Some podocyte cell bodies appeared swollen, and there was some villous transformation and microvesiculation of the podocyte plasma membranes. In most areas of the glomerulus, foot processes appeared normal, but in other areas, there were abnormalities, ranging from short and widened foot processes to patchy effacement (Fig. 8B). Anti-GBM-injected $iPLA_2\gamma$ KO mice showed substantially more severe abnormalities in podocyte ultrastructure. Podocyte cell bodies were swollen with fewer organelles, and there was extensive villous transformation and microvesiculation of the plasma membranes. Foot processes were severely malformed and were effaced extensively (Fig. 8C). However, there were no apparent abnormalities in the ultrastructure of organelles, including mitochondria, and no apparent autophagosomes. There was an absence of leukocytes in the glomeruli. To quantify podocyte foot process effacement objectively, we measured foot process width in $iPLA_2\gamma$ KO and WT mice in both saline- and anti-GBM-injected groups. The anti-GBM-injected $iPLA_2\gamma$ KO mice showed the greatest foot process width, indicating severe foot process effacement (Fig. 8D). Taken together, deletion of $iPLA_2\gamma$ in anti-GBM nephritis induced severe abnormalities in podocyte ultrastructure, which are in keeping with the increased level of albuminuria in these mice.




FIGURE 7. *iPLA₂γ* deletion exacerbates albuminuria in anti-GBM nephritis. Nephritis was induced in WT and *iPLA₂γ* KO mice (3–4 months of age) via single intravenous injection of sheep anti-rat GBM antiserum (aGBM). Control mice received saline. The urinary albumin/creatinine ratio was measured before and 24 h after the injection. **A**, after the induction of anti-GBM nephritis, *iPLA₂γ* KO mice had greater albuminuria compared with WT. *, $p < 0.05$, *iPLA₂γ* KO anti-GBM versus WT anti-GBM. KO anti-GBM, $n = 7$ mice (4 females and 3 males); WT anti-GBM, $n = 7$ mice (2 females and 5 males); KO control, $n = 4$ mice; WT control, $n = 4$ mice. **B**, immunofluorescence staining for sheep (Sh) anti-GBM IgG and mouse complement C3 in mice with anti-GBM nephritis (at 24 h). There is bright glomerular fluorescence staining for sheep IgG in both WT and *iPLA₂γ* KO mice. Fainter glomerular C3 staining was present in both groups of mice. The C3 staining of Bowman's capsule (surrounding the glomerulus) is observed in normal mouse kidneys and is not due to the administration of anti-GBM antibody. Bar, 20 μ m. **C**, quantification of anti-GBM antibody and complement C3 deposition (fluorescence intensity) in arbitrary units shows no significance differences between groups. Error bars, S.E.

***iPLA₂γ* Deletion Induces Marked Podocyte Loss in Anti-GBM Nephritis**—In addition to albuminuria, glomerular injury may be associated with loss of podocytes. To provide further evidence for a cytoprotective effect of *iPLA₂γ* *in vivo*, we quantified the number of podocyte nuclei in glomeruli of KO and WT mice by WT1 immunostaining. In saline-treated mice (age 3

months), deletion of *iPLA₂γ* did not alter the number of WT1-positive cells compared with WT. Furthermore, in WT mice, injection of anti-GBM antiserum did not alter the number of WT1-positive cells. In contrast, there was a ~60% decrease in the number of WT1-positive cells in *iPLA₂γ* KO glomeruli after anti-GBM antiserum injection (Fig. 9, **A** and **B**). Therefore, genetic ablation of *iPLA₂γ* induced a marked loss of podocytes after these cells were subjected to injury. Taken together, the results indicate that *iPLA₂γ* exerts a cytoprotective effect on the podocyte and glomerular injury *in vivo*.

Effects of *iPLA₂γ* Deletion on Expression of Nephlin and ER Stress Proteins in Anti-GBM Nephritis—The expression of nephlin was examined by immunofluorescence microscopy and was then quantified. In parallel with albuminuria, anti-GBM antibody induced a decrease in nephlin expression in both WT and *iPLA₂γ* KO mice; nephlin expression tended to be lower in *iPLA₂γ* KO mice, compared with WT, but the difference did not reach statistical significance (Fig. 9, **A** and **C**). By immunoblotting, expression of the mature form of nephlin was reduced markedly in anti-GBM nephritis but comparably in WT and *iPLA₂γ* KO mice (Fig. 10, **A** (top nephlin band) and **B**). Furthermore, the amount of mature nephlin (top band) was reduced significantly relative to the ER form (bottom band) in anti-GBM nephritic mice (Fig. 10, **A** and **C**). These results imply that in anti-GBM nephritis, there is defective glycosylation of nephlin due to ER dysfunction, although this appears to be largely independent of *iPLA₂γ*.

To further address the role of *iPLA₂γ* in ER function *in vivo*, we monitored the unfolded protein response (*i.e.* changes in the expression of ER chaperones after induction of anti-GBM nephritis). Glomerular GRP94 and GRP78 (BiP) were up-regulated significantly in the KO anti-GBM mice but not in WT (Fig. 10, **A**, **D**, and **E**). There were no consistent changes in CHOP (CCAAT/enhancer-binding protein homologous protein) among groups (results not shown). These results imply that deletion of *iPLA₂γ* in the context of glomerulonephritis leads to amplification of the adaptive unfolded protein response. The dose of anti-GBM antibody used in this study was low, allowing us to ascertain differences in albuminuria between *iPLA₂γ* and WT mice. At substantially higher doses of antibody, WT mice with anti-GBM nephritis also show comparable increases in glomerular expression of GRP94 and BiP (results not shown). However, at these higher doses, albuminuria is massive and does not allow for the study of *iPLA₂γ* effects.

Mitochondrial Injury Enhances Complement-mediated Cytotoxicity—The primary pathological finding in aging *iPLA₂γ* KO mice is mitochondrial damage in podocytes (Fig. 2). Compared with WT, *iPLA₂γ* KO mice (age 3 months) showed greater albuminuria and podocyte injury after induction of anti-GBM nephritis (Figs. 7A and 8), but mitochondrial ultrastructural damage in the podocytes was not observed. Nevertheless, to determine whether enhanced complement-mediated podocyte injury in anti-GBM nephritis in the *iPLA₂γ* KO mice may have been associated with underlying mitochondrial dysfunction, we examined the role of the mitochondria in complement-dependent cytolysis in cultured GECs. We pre-treated GECs with antimycin A to impair mitochondrial function. Then both untreated and antimycin A-treated GECs were




FIGURE 8. *iPLA₂γ* deletion exacerbates abnormalities in podocyte ultrastructure in anti-GBM nephritis. Kidneys of four albuminuric mice (two *iPLA₂γ* KO and two WT; 3–5 glomeruli/mouse) and three control mice (saline-treated groups) were examined by electron microscopy. *A*, an *iPLA₂γ* KO mouse (age 3 months) injected with saline shows normal podocyte ultrastructure. Foot processes, cell bodies, and intracellular organelles appear intact (bar, 500 nm). *B*, WT mouse (age 3 months) injected with anti-GBM antibody. In this electron micrograph, podocyte foot processes appear widened with segmental effacement. There is some villous transformation of the podocyte plasma membranes. *C*, *iPLA₂γ* KO mouse (age 3 months) injected

incubated with antibody and complement, and cytotoxicity was monitored by release of LDH. As expected, complement-mediated cytotoxicity increased with serially increasing doses of complement, and pretreatment of cells with antimycin A enhanced complement-mediated cytotoxicity at every dose (Fig. 11). For comparison, in analogous experiments, GECs were pretreated with tunicamycin, which induces cytotoxic ER stress (21). Tunicamycin did not, however, enhance complement cytotoxicity (data not shown). These results indicate that mitochondrial dysfunction in cultured GECs enhances complement-mediated cytotoxicity and support the view that exacerbation of GEC injury in anti-GBM nephritis in the *iPLA₂γ* KO mice was associated with underlying mitochondrial dysfunction.

Discussion

In this study, we demonstrated that deletion of *iPLA₂γ* resulted in striking mitochondrial abnormalities in GECs/podocytes of 10–11-month-old mice (Fig. 2). These ultrastructural abnormalities were widespread and included disruption of membranes, loss of cristae, fission, and aggregation (Fig. 2). Aging *iPLA₂γ* KO mice also demonstrated podocyte plasma membrane damage and slight but significant widening of foot processes compared with WT (Fig. 2). Expression of synaptopodin was lower in *iPLA₂γ* KO glomeruli (Figs. 3 and 4), and there was a ~25% decrease in the number of WT1-positive cells in *iPLA₂γ* KO glomeruli compared with control (Fig. 3), implying that deletion of *iPLA₂γ* induced a loss of podocytes. In association with mitochondrial damage, phosphorylation of AMPK was increased in *iPLA₂γ* KO glomeruli (Fig. 4), consistent with reduced ATP generation by mitochondria in KO podocytes leading to podocyte injury. In the aging *iPLA₂γ* KO mice, some podocytes contained prominent autophagic vacuoles (Fig. 2). There was also an increase in the glomerular ratio of LC3-II/LC3-I protein expression in KO mice, in keeping with accumulation of autophagic vacuoles (Fig. 4). Surprisingly, the ultrastructural abnormalities in aging podocytes were not associated with development of albuminuria (Fig. 1) or renal failure, although these could potentially appear at a more advanced age. Studies in cultured GECs derived from WT and *iPLA₂γ* KO mice showed that deletion of *iPLA₂γ* impaired mitochondrial function and enhanced autophagy (Figs. 5 and 6). Indeed, the clustering of mitochondria in the perinuclear regions of cells (as observed in *iPLA₂γ* KO GECs) is reported to be associated with autophagy (36). Thus, the GEC culture studies recapitulate the phenotype *in vivo* and support the functional importance of the ultrastructural findings and low cell energy stores in *iPLA₂γ* KO glomeruli.

In cells, *iPLA₂γ* is localized at the mitochondria, ER, and peroxisomes (3). There are several variants of *iPLA₂γ*, and subcellular localization may, at least in part, depend on the variant expressed in the specific cell type (3, 20, 37). Previously, we demonstrated that *iPLA₂γ* mRNA and protein of 88 kDa are

with anti-GBM antibody. Podocyte cell bodies appear swollen, and the cell membranes show marked villous transformation and microvesiculation. Podocyte foot processes are almost completely effaced. *D*, quantification of foot process width in *iPLA₂γ*-KO and WT mice. *, $p < 0.0001$ KO/anti-GBM versus other groups, 9–36 measurements/group. Error bars, S.E.




FIGURE 9. Immunofluorescence staining for WT1 and nephrin in anti-GBM nephritis. A and B, *iPLA₂γ* deletion reduced podocyte number in anti-GBM nephritis. WT1 immunofluorescence was assessed in two WT mice without and with anti-GBM antibody and four *iPLA₂γ* KO mice (age 3–4 months), without and with anti-GBM antibody. Bar, 20 μ m. B, quantification of WT1-positive nuclei per glomerulus (25–36 glomeruli/group). *, $p < 0.001$ KO/anti-GBM versus WT/anti-GBM. A and C, nephrin immunofluorescence intensity was assessed in *iPLA₂γ* KO mice without ($n = 2$) and with anti-GBM antibody ($n = 6$) and in WT mice without ($n = 2$) and with anti-GBM antibody ($n = 5$). *, $p < 0.0001$ anti-GBM versus saline (14–31 measurements/group). Error bars, S.E.

expressed in the glomerulus *in vivo* (19). GFP-tagged *iPLA₂γ* was localized at the ER and mitochondria in cultured GECs, and this pattern of localization was dependent on the N-terminal domain of *iPLA₂γ* (20). Our results in podocytes are in keeping with previous studies, where deletion of *iPLA₂γ* in mice resulted in mitochondrial disruption. For example, deletion of *iPLA₂γ* induced mitochondrial dysfunction in the heart, skeletal muscle, liver, and brain (7, 8, 10, 11). *iPLA₂γ* KO mice displayed cold intolerance, a defect in mitochondrial cytochrome oxidase, and multiple bioenergetic dysfunctional phenotypes at 4–6 months of age (7). In skeletal muscle of 4-month-old KO mice, there was mitochondrial dysfunction, oxidative stress, and lipid peroxidation (11). These mice exhibited growth retardation. *iPLA₂γ* deletion induced significant changes in mitochondrial phospholipid homeostasis (see below). In aging mice (10 months), this was associated with ultrastructural evidence for enlarged and degenerating mitochondria in the brain, autophagy, and cognitive dysfunction (8). These studies identified an obligatory role for *iPLA₂γ* in mitochondrial structure.

Increased autophagy in podocytes of 10–11-month-old *iPLA₂γ* KO mice (Fig. 2) may have been triggered by reduced ATP levels and activation of AMPK (Fig. 4). Actually, AMPK has been implicated as an important positive regulator of autophagy (30, 31). Autophagy was less likely to have been due to ER stress, since there was no evidence for significant ER dysfunction in *iPLA₂γ* KO mice (Fig. 4). It has been suggested that in podocytes, reduced ubiquitin-proteasome function

might result in increased autophagy (30, 38). We did not, however, observe any differences in polyubiquitination of glomerular proteins between *iPLA₂γ* KO and WT mice (result not shown). Determination of whether cross-talk between these two systems plays a mechanistic role in injury will require further study. In *iPLA₂γ* KO podocytes, autophagy may promote survival by improving cell energy levels. Enhanced autophagy in podocytes as well as in the brains of *iPLA₂γ* KO mice may also be a cytoprotective mechanism to clear damaged mitochondria from the cytoplasm (30, 31, 38). Based on a study in *Atg5* KO mice, autophagy appears to be a homeostatic mechanism to maintain podocyte integrity and a protective mechanism against aging and glomerular injury (30).

It should be noted that in contrast to podocytes, mitochondria in other kidney cell types, including parietal epithelial cells and proximal tubular epithelial cells in *iPLA₂γ* KO mice, showed normal ultrastructure (Fig. 2). This finding in proximal tubular epithelial cells was unexpected because the function of these cells is highly dependent on mitochondrial energy production, and depletion of *iPLA₂γ* in cultured proximal tubular epithelial cells in previous studies resulted in metabolic abnormalities (see below) (22). In contrast to podocytes, which appear to contain relatively few, small mitochondria, tubular cells *in vivo* contain numerous, large mitochondria (Fig. 2). Perhaps a more robust mitochondrial structure allowed the tubular cells to withstand potential damage from the deletion of *iPLA₂γ* *in vivo*. Alternatively, there may be differences in

Podocyte Injury in iPLA₂γ Knock-out Mice




FIGURE 10. Effect of iPLA₂γ on the expression of nephrin and ER stress proteins in anti-GBM nephritis. Glomeruli were isolated from 3-month-old WT and iPLA₂γ KO mice that were treated with anti-GBM antibody or saline (at 24 h). Lysates were immunoblotted as indicated. *A*, representative immunoblots. The white lines indicate reassembly of noncontiguous gel lanes. There were no adjustments made to the digital images among the lanes that would alter the information in the panels. *B–E*, densitometric quantification. *B* and *C*, anti-GBM antibody reduced expression of mature nephrin (top nephrin band) as well as maturation of nephrin (ratio of top to bottom band) in both WT and iPLA₂γ KO mice. *B*, *, $p < 0.02$; **, $p < 0.01$, anti-GBM versus saline (3–4 mice/group). *C*, *, $p = 0.05$; **, $p < 0.02$ anti-GBM versus saline (3–4 mice/group). *D* and *E*, anti-GBM antibody increased expression of GRP94 and BiP (GRP78) in iPLA₂γ KO mice. *D*, *, $p < 0.005$ KO/anti-GBM versus KO/saline (3–4 mice/group). *E*, *, $p < 0.02$, KO/anti-GBM versus KO/saline (3–4 mice/group). Error bars, S.E.

iPLA₂γ variants, expression, or activation among the renal cell types. Finally, certain cells may activate alternate mechanisms to compensate for iPLA₂γ deficiency, or the podocyte, a cell with limited proliferative capacity (12, 14), may not be able to withstand mitochondrial damage, unlike proximal tubular cells, which have high potential for proliferation and repair from injury (39).

In regard to its role in lipid homeostasis, deletion of iPLA₂γ resulted in a decrease in cardiolipin content and altered cardiolipin molecular species distribution in heart and skeletal muscle mitochondria, but there were no significant changes in phospholipids and triglycerides (7, 9, 11). In brain hippocampal




FIGURE 11. Mitochondrial injury enhances complement-mediated cytotoxicity. Cultured GECs were preincubated with or without antimycin A (10 μM, 30 min). Then untreated and antimycin A-treated GECs were incubated with anti-GEC antibody (40 min) and complement (5, 10, and 15% normal serum; heat-inactivated serum in controls) for 40 min. Cytolysis was monitored by release of LDH. *, $p < 0.001$ antimycin A versus untreated (four experiments). Antimycin A had no significant independent effect on cytolysis. Error bars, S.E.

lipid extracts, iPLA₂γ KO mice showed an increase in various cardiolipin molecular species, increases in arachidonoyl-phosphatidylcholine and oxidized phosphatidylethanolamine, an increase in ceramide, and a decrease in plasmalogen-phosphatidylethanolamine (8). Decreased iPLA₂γ expression in cultured renal proximal tubular cells mildly enhanced phosphatidylcholine and phosphatidylethanolamine levels (22). Cardiolipin is an important mitochondrial lipid, and proper remodeling of cardiolipin is essential for efficient electron transport chain function. Defects in cardiolipin have also been associated with aging. Thus, abnormal cardiolipin remodeling in iPLA₂γ-deficient cells would be expected to result in defective electron coupling and bioenergetic inefficiency (8). It should be noted that although distinct directional changes in cardiolipin levels were observed in the heart and brain, mitochondrial function was impaired in both instances. Furthermore, disruption of iPLA₂γ-mediated release of fatty acids may impair important signaling that is required for mitochondrial function (9).

The podocyte plays a key role in maintaining glomerular permselectivity. In normal podocytes, actin filaments are the core structural components of foot processes. Studies predominantly in cell culture models suggest that podocytes require a high energy supply to maintain various cellular functions, including the organization of cytoskeletal and GBM proteins (40). Condensation of the actin cytoskeleton at the base of effaced podocyte foot processes, together with alterations in filtration slits and displacement and disruption of slit diaphragms, are features of established proteinuric glomerular diseases (12–14, 17). As noted above, podocyte injury was observed in aging iPLA₂γ KO mice (Fig. 2), but this was not associated with albuminuria (Fig. 1). Possibly, there was sufficient mitochondrial reserve, and the podocytes were able to maintain their permselective function. Despite the ~25% loss of podocytes, the remaining podocytes may have been able to stretch and/or hypertrophy to compensate for the decreased number. Actually, the loss of podocytes may have been below the threshold required to produce extensive GBM denudation, proteinuria, and sclerotic lesions (16, 41, 42). In another mouse model of mitochondrial dysfunction, due to deletion of the *Mpv17* gene, which is expressed in podocytes, albuminuria and

mild glomerular sclerotic lesions developed only at 18 months of age (43).

Induction of podocyte injury with anti-GBM antibody revealed a protective phenotype of iPLA₂γ in young mice. In heterologous anti-GBM nephritis, activation of complement and assembly of C5b-9 induces podocyte “stress” (24, 34, 35). iPLA₂γ KO mice with anti-GBM nephritis had increased albuminuria and a remarkable reduction in podocytes compared with WT mice (Figs. 7 and 9; see below). Moreover, iPLA₂γ KO mice showed substantially more severe abnormalities in podocyte ultrastructure, including swelling of cell bodies, marked villous transformation, and microvesiculation of plasma membranes, and almost complete foot process effacement (Fig. 8). Although structural abnormalities in podocyte organelles were not evident, studies in cultured GECs demonstrated that mitochondrial dysfunction can enhance complement-mediated cytotoxicity (Fig. 11), implying that podocyte injury in anti-GBM nephritis in iPLA₂γ KO mice was most likely exacerbated due to underlying mitochondrial dysfunction. The association of podocyte mitochondrial dysfunction with proteinuria has been reported (40). By analogy to our study, after induction of anti-GBM nephritis in mice with mitochondrial dysfunction (*Mpv17* gene deletion), the KO mice had greater levels of albuminuria compared with control, although the anti-GBM model employed in this study was more chronic (4 days) (43). We focused on anti-GBM nephritis at 24 h (the phase when mediation of the disease is more restricted to complement). In acute anti-GBM nephritis, ultrastructural changes in mitochondria may take a longer time to develop, or alternatively, the podocytes with injured mitochondria may have been those lost into the urine due to detachment from the GBM. Based on these results, it is reasonable to conclude that iPLA₂γ is cytoprotective. This *in vivo* result is consistent with earlier studies, which showed that increased expression of iPLA₂γ in cultured GECs reduced complement-mediated GEC injury (19).

As noted above, deletion of iPLA₂γ resulted in a decrease in podocyte number in aging mice (Fig. 2) and a more marked decrease in podocytes in younger mice with anti-GBM nephritis (Fig. 9). There is both experimental and clinical evidence to support the view that podocyte apoptosis leads to glomerular disease and proteinuria (14, 16, 41, 42). The presence of iPLA₂γ at the mitochondria may therefore provide an anti-apoptotic effect in the aging kidney and in anti-GBM nephritis. A second possibility is that loss of podocytes is due to podocyte detachment from the GBM and the subsequent appearance of viable cells in the urine (44, 45). iPLA₂γ deletion potentially impairs the energy required for the production or function of proteins involved in mediating podocyte foot process adhesion to the GBM. Additional proof of these mechanisms will require further study.

Although we previously showed that the presence of iPLA₂γ at the ER is functionally important in terms of ER signaling in cultured GECs (21), deletion of iPLA₂γ in aging mice did not lead to any apparent abnormalities in ER morphology or function (Figs. 2–4). However, glomerular expression of the ER chaperones, BiP and GRP94, was increased in iPLA₂γ KO mice with anti-GBM nephritis (Fig. 10), implying that deletion of iPLA₂γ in the context of nephritis enhanced the adaptive

unfolded protein response, particularly activation of the ATF6 pathway (38, 46, 47). This result is apparently discrepant from an earlier study, where it was demonstrated that overexpression of iPLA₂γ enhanced ATF6 activation, whereas deletion reduced activation in cultured GECs (21). The reason for this discrepancy will require further elucidation; however, it is likely that multiple signaling pathways are activated by complement in the *in vivo* anti-GBM nephritis model (18), and a number of these could potentially impact the unfolded protein response. Activation of the adaptive unfolded response in anti-GBM nephritis is similar to experimental membranous nephropathy, a glomerular disease mediated by complement C5b-9 (17, 38, 46).

In conclusion, the results of this study demonstrate an important role for iPLA₂γ in maintaining podocyte integrity both in the normal kidney and in glomerular disease. In the future, modulation of iPLA₂γ enzymatic activity may potentially represent a novel approach to limiting GEC injury and proteinuria.

Author Contributions—H. E., A. V. C., and T. T. designed the study and wrote the paper. H. E., J. P., J. G., and L. A. conducted experiments. D. R. K. designed the experiments in Figs. 4 and 5. R. W. G. produced the knock-out mice. All authors analyzed the results and approved the manuscript.

References

1. Murakami, M., and Kudo, I. (2002) Phospholipase A₂. *J. Biochem.* **131**, 285–292
2. Six, D. A., and Dennis, E. A. (2000) The expanding superfamily of phospholipase A₂ enzymes: classification and characterization. *Biochim. Biophys. Acta* **1488**, 1–19
3. Ramanadham, S., Ali, T., Ashley, J. W., Bone, R. N., Hancock, W. D., and Lei, X. (2015) Calcium-independent phospholipases A₂ and their roles in biological processes and diseases. *J. Lipid Res.* **56**, 1643–1668
4. Schaloske, R. H., and Dennis, E. A. (2006) The phospholipase A₂ superfamily and its group numbering system. *Biochim. Biophys. Acta* **1761**, 1246–1259
5. Mancuso, D. J., Jenkins, C. M., and Gross, R. W. (2000) The genomic organization, complete mRNA sequence, cloning, and expression of a novel human intracellular membrane-associated calcium-independent phospholipase A₂. *J. Biol. Chem.* **275**, 9937–9945
6. Tanaka, H., Takeya, R., and Sumimoto, H. (2000) A novel intracellular membrane-bound calcium-independent phospholipase A₂. *Biochem. Biophys. Res. Commun.* **272**, 320–326
7. Mancuso, D. J., Sims, H. F., Han, X., Jenkins, C. M., Guan, S. P., Yang, K., Moon, S. H., Pietka, T., Abumrad, N. A., Schlesinger, P. H., and Gross, R. W. (2007) Genetic ablation of calcium-independent phospholipase A₂γ leads to alterations in mitochondrial lipid metabolism and function resulting in a deficient mitochondrial bioenergetic phenotype. *J. Biol. Chem.* **282**, 34611–34622
8. Mancuso, D. J., Kotzbauer, P., Wozniak, D. F., Sims, H. F., Jenkins, C. M., Guan, S., Han, X., Yang, K., Sun, G., Malik, I., Conyers, S., Green, K. G., Schmidt, R. E., and Gross, R. W. (2009) Genetic ablation of calcium-independent phospholipase A₂γ leads to alterations in hippocampal cardiolipin content and molecular species distribution, mitochondrial degeneration, autophagy, and cognitive dysfunction. *J. Biol. Chem.* **284**, 35632–35644
9. Mancuso, D. J., Sims, H. F., Yang, K., Kiebish, M. A., Su, X., Jenkins, C. M., Guan, S., Moon, S. H., Pietka, T., Nassir, F., Schappe, T., Moore, K., Han, X., Abumrad, N. A., and Gross, R. W. (2010) Genetic ablation of calcium-independent phospholipase A₂γ prevents obesity and insulin resistance during high fat feeding by mitochondrial uncoupling and increased adi-

- pocyte fatty acid oxidation. *J. Biol. Chem.* **285**, 36495–36510
10. Moon, S. H., Jenkins, C. M., Kiebish, M. A., Sims, H. F., Mancuso, D. J., and Gross, R. W. (2012) Genetic ablation of calcium-independent phospholipase A₂γ (iPLA₂γ) attenuates calcium-induced opening of the mitochondrial permeability transition pore and resultant cytochrome *c* release. *J. Biol. Chem.* **287**, 29837–29850
11. Yoda, E., Hachisu, K., Taketomi, Y., Yoshida, K., Nakamura, M., Ikeda, K., Taguchi, R., Nakatani, Y., Kuwata, H., Murakami, M., Kudo, I., and Hara, S. (2010) Mitochondrial dysfunction and reduced prostaglandin synthesis in skeletal muscle of Group VIB Ca²⁺-independent phospholipase A₂γ-deficient mice. *J. Lipid Res.* **51**, 3003–3015
12. Pavenstädt, H., Kriz, W., and Kretzler, M. (2003) Cell biology of the glomerular podocyte. *Physiol. Rev.* **83**, 253–307
13. Chiang, C. K., and Inagi, R. (2010) Glomerular diseases: genetic causes and future therapeutics. *Nat. Rev. Nephrol.* **6**, 539–554
14. Greka, A., and Mundel, P. (2012) Cell biology and pathology of podocytes. *Annu Rev. Physiol.* **74**, 299–323
15. Welsh, G. I., and Saleem, M. A. (2012) The podocyte cytoskeleton: key to a functioning glomerulus in health and disease. *Nat. Rev. Nephrol.* **8**, 14–21
16. Pippin, J. W., Brinkkoetter, P. T., Cormack-Aboud, F. C., Durvasula, R. V., Hauser, P. V., Kowalewska, J., Krofft, R. D., Logar, C. M., Marshall, C. B., Ohse, T., and Shankland, S. J. (2009) Inducible rodent models of acquired podocyte diseases. *Am. J. Physiol. Renal Physiol.* **296**, F213–F229
17. Cybulsky, A. V. (2011) Membranous nephropathy. *Contrib. Nephrol.* **169**, 107–125
18. Takano, T., Elimam, H., and Cybulsky, A. V. (2013) Complement-mediated cellular injury. *Semin. Nephrol.* **33**, 586–601
19. Cohen, D., Papillon, J., Aoudjit, L., Li, H., Cybulsky, A. V., and Takano, T. (2008) Role of calcium-independent phospholipase A₂ in complement-mediated glomerular epithelial cell injury. *Am. J. Physiol. Renal Physiol.* **294**, F469–F479
20. Elimam, H., Papillon, J., Takano, T., and Cybulsky, A. V. (2013) Complement-mediated activation of calcium-independent phospholipase A₂γ: role of protein kinases and phosphorylation. *J. Biol. Chem.* **288**, 3871–3885
21. Elimam, H., Papillon, J., Takano, T., and Cybulsky, A. V. (2015) Calcium-independent phospholipase A₂γ enhances activation of the ATF6 transcription factor during endoplasmic reticulum stress. *J. Biol. Chem.* **290**, 3009–3020
22. Kinsey, G. R., Blum, J. L., Covington, M. D., Cummings, B. S., McHowat, J., and Schnellmann, R. G. (2008) Decreased iPLA₂γ expression induces lipid peroxidation and cell death and sensitizes cells to oxidant-induced apoptosis. *J. Lipid Res.* **49**, 1477–1487
23. N'Diaye, E. N., Kajihara, K. K., Hsieh, I., Morisaki, H., Debnath, J., and Brown, E. J. (2009) PLIC proteins or ubiquilins regulate autophagy-dependent cell survival during nutrient starvation. *EMBO Rep.* **10**, 173–179
24. Salant, D. J., and Cybulsky, A. V. (1988) Experimental glomerulonephritis. *Methods Enzymol.* **162**, 421–461
25. Drozdova, T., Papillon, J., and Cybulsky, A. V. (2013) Nephron missense mutations: induction of endoplasmic reticulum stress and cell surface rescue by reduction in chaperone interactions. *Physiol. Rep.* **1**, e00086
26. Nezvitsky, L., Tremblay, M. L., Takano, T., Papillon, J., and Cybulsky, A. V. (2014) Complement-mediated glomerular injury is reduced by inhibition of protein-tyrosine phosphatase 1B. *Am. J. Physiol. Renal Physiol.* **307**, F634–F647
27. van den Berg, J. G., van den Bergh Weerman, M. A., Assmann, K. J., Weening, J. J., and Florquin, S. (2004) Podocyte foot process effacement is not correlated with the level of proteinuria in human glomerulopathies. *Kidney Int.* **66**, 1901–1906
28. Bechtel, W., Helmstädt, M., Balica, J., Hartleben, B., Kiefer, B., Hrnjic, F., Schell, C., Kretz, O., Liu, S., Geist, F., Kerjaschki, D., Walz, G., and Huber, T. B. (2013) Vps34 deficiency reveals the importance of endocytosis for podocyte homeostasis. *J. Am. Soc. Nephrol.* **24**, 727–743
29. Kreidberg, J. A. (2003) Podocyte differentiation and glomerulogenesis. *J. Am. Soc. Nephrol.* **14**, 806–814
30. Huber, T. B., Edelstein, C. L., Hartleben, B., Inoki, K., Jiang, M., Koya, D., Kume, S., Lieberthal, W., Pallet, N., Quiroga, A., Ravichandran, K., Susztak, K., Yoshida, S., and Dong, Z. (2012) Emerging role of autophagy in kidney function, diseases and aging. *Autophagy* **8**, 1009–1031
31. Periyasamy-Thandavan, S., Jiang, M., Schoenlein, P., and Dong, Z. (2009) Autophagy: molecular machinery, regulation, and implications for renal pathophysiology. *Am. J. Physiol. Renal Physiol.* **297**, F244–F256
32. Johnson, L. V., Walsh, M. L., Bockus, B. J., and Chen, L. B. (1981) Monitoring of relative mitochondrial membrane potential in living cells by fluorescence microscopy. *J. Cell Biol.* **88**, 526–535
33. Mizushima, N., Yoshimori, T., and Levine, B. (2010) Methods in mammalian autophagy research. *Cell* **140**, 313–326
34. Couser, W. G., Baker, P. J., and Adler, S. (1985) Complement and the direct mediation of immune glomerular injury: a new perspective. *Kidney Int.* **28**, 879–890
35. Lin, F., Emancipator, S. N., Salant, D. J., and Medof, M. E. (2002) Decay-accelerating factor confers protection against complement-mediated podocyte injury in acute nephrotoxic nephritis. *Lab. Invest.* **82**, 563–569
36. Gomes, L. C., and Scorrano, L. (2013) Mitochondrial morphology in mitophagy and macroautophagy. *Biochim. Biophys. Acta* **1833**, 205–212
37. Mancuso, D. J., Jenkins, C. M., Sims, H. F., Cohen, J. M., Yang, J., and Gross, R. W. (2004) Complex transcriptional and translational regulation of iPLA₂γ resulting in multiple gene products containing dual competing sites for mitochondrial or peroxisomal localization. *Eur. J. Biochem.* **271**, 4709–4724
38. Cybulsky, A. V. (2013) The intersecting roles of endoplasmic reticulum stress, ubiquitin-proteasome system, and autophagy in the pathogenesis of proteinuric kidney disease. *Kidney Int.* **84**, 25–33
39. Bonventre, J. V., and Yang, L. (2011) Cellular pathophysiology of ischemic acute kidney injury. *J. Clin. Invest.* **121**, 4210–4221
40. Muller-Deile, J., and Schiffer, M. (2014) The podocyte power-plant disaster and its contribution to glomerulopathy. *Front. Endocrinol.* **5**, 209
41. D'Agati, V. D. (2008) Podocyte injury in focal segmental glomerulosclerosis: Lessons from animal models (a play in five acts). *Kidney Int.* **73**, 399–406
42. Wiggins, R. C. (2007) The spectrum of podocytopathies: a unifying view of glomerular diseases. *Kidney Int.* **71**, 1205–1214
43. Casalena, G., Krick, S., Daehn, I., Yu, L., Ju, W., Shi, S., Tsai, S. Y., D'Agati, V., Lindenmeyer, M., Cohen, C. D., Schlondorff, D., and Bottinger, E. P. (2014) Mpv17 in mitochondria protects podocytes against mitochondrial dysfunction and apoptosis *in vivo* and *in vitro*. *Am. J. Physiol. Renal Physiol.* **306**, F1372–F1380
44. Petermann, A. T., Krofft, R., Blonski, M., Hiromura, K., Vaughn, M., Pichler, R., Griffin, S., Wada, T., Pippin, J., Durvasula, R., and Shankland, S. J. (2003) Podocytes that detach in experimental membranous nephropathy are viable. *Kidney Int.* **64**, 1222–1231
45. Petermann, A. T., Pippin, J., Krofft, R., Blonski, M., Griffin, S., Durvasula, R., and Shankland, S. J. (2004) Viable podocytes detach in experimental diabetic nephropathy: potential mechanism underlying glomerulosclerosis. *Nephron Exp. Nephrol.* **98**, e114–e123
46. Cybulsky, A. V. (2010) Endoplasmic reticulum stress in proteinuric kidney disease. *Kidney Int.* **77**, 187–193
47. Inagi, R., Ishimoto, Y., and Nangaku, M. (2014) Proteostasis in endoplasmic reticulum: new mechanisms in kidney disease. *Nat. Rev. Nephrol.* **10**, 369–378

Genetic Ablation of Calcium-independent Phospholipase A₂ γ Induces Glomerular Injury in Mice

Hanan Elimam, Joan Papillon, Daniel R. Kaufman, Julie Guillemette, Lamine Aoudjit, Richard W. Gross, Tomoko Takano and Andrey V. Cybulsky

J. Biol. Chem. 2016, 291:14468-14482.

doi: 10.1074/jbc.M115.696781 originally published online May 12, 2016

Access the most updated version of this article at doi: [10.1074/jbc.M115.696781](https://doi.org/10.1074/jbc.M115.696781)

Alerts:

- [When this article is cited](#)
- [When a correction for this article is posted](#)

[Click here](#) to choose from all of JBC's e-mail alerts

This article cites 47 references, 22 of which can be accessed free at <http://www.jbc.org/content/291/28/14468.full.html#ref-list-1>